Biliary Tract Cancers, Version 2.2023 Featured Updates to the NCCN Guidelines

Al B. Benson; Michael I. D’Angelica; Thomas Abrams; Daniel E. Abbott; Aijaz Ahmed; Daniel A. Anaya; Robert Anders; Chandrakanth Are; Melinda Bachini; David Binder; Mitesh Borad; Christopher Bowlus; Daniel Brown; Adam Burgoyne; Jason Castellanos; Prabhleen Chahal; Jordan Cloyd; Anne M. Covey; Evan S. Glazer; William G. Hawkins; Renuka Iyer; Rojymon Jacob; Lawrence Jennings; R. Kate Kelley; Robin Kim; Matthew Levine; Manisha Palta; James O. Park; Steven Raman; Sanjay Reddy; Sean Ronnekleiv-Kelly; Vaibhav Sahai; Gagandeep Singh; Stacey Stein; Anita Turk; Jean-Nicolas Vauthey; Alan P. Venook; Adam Yopp; Nicole McMillian; Ryan Schonfeld; Cindy Hochstetler

doi:10.6004/jnccn.2023.0035

Back

Biliary Tract Cancers, Version 2.2023 Featured Updates to the NCCN Guidelines

Journal article

Open access

Peer reviewed

Biliary Tract Cancers, Version 2.2023 Featured Updates to the NCCN Guidelines

Al B. Benson, Michael I. D’Angelica, Thomas Abrams, Daniel E. Abbott, Aijaz Ahmed, Daniel A. Anaya, Robert Anders, Chandrakanth Are, Melinda Bachini, David Binder, …

JNCCN Journal of the National Comprehensive Cancer Network, Vol.21(7)

2023

DOI: https://doi.org/10.6004/jnccn.2023.0035

Abstract

Bile Duct Neoplasms

Bile Ducts, Intrahepatic

Biliary Tract Neoplasms

Cholangiocarcinoma

Gallbladder Neoplasms

Humans

Liver Neoplasms

antineoplastic agent

B Raf kinase

entrectinib

epidermal growth factor receptor 2

fibroblast growth factor receptor

fibroblast growth factor receptor 2

immune checkpoint inhibitor

isocitrate dehydrogenase 1

K ras protein

larotrectinib

programmed death 1 ligand 1

protein Ret

reactive oxygen metabolite

Article

biliary tract cancer

cancer immunotherapy

cancer therapy

gene mutation

gene overexpression

human

inoperable cancer

metastasis

molecularly targeted therapy

practice guideline

systemic therapy

bile duct carcinoma

bile duct tumor

biliary tract tumor

gallbladder tumor

intrahepatic bile duct

liver tumor

In 2023, the NCCN Guidelines for Hepatobiliary Cancers were divided into 2 separate guidelines: Hepatocellular Carcinoma and Biliary Tract Cancers. The NCCN Guidelines for Biliary Tract Cancers provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts meets at least on an annual basis to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. These Guidelines Insights focus on some of the recent updates to the NCCN Guidelines for Biliary Tract Cancers as well as the newly published section on principles of molecular testing. © 2023 National Comprehensive Cancer Network® (NCCN®), All rights reserved.

Files and links (1)

url

https://doi.org/10.6004/jnccn.2023.0035View

Published (Version of record) Open

Metrics

1 Record Views

See more details

Details

Title: Biliary Tract Cancers, Version 2.2023 Featured Updates to the NCCN Guidelines
Creators: Al B. Benson - Amgen
Michael I. D’Angelica - Memorial Sloan Kettering Cancer Center
Thomas Abrams - Dana-Farber Brigham Cancer Center
Daniel E. Abbott - University of Wisconsin Carbone Cancer Center
Aijaz Ahmed - Stanford Cancer Institute
Daniel A. Anaya - Moffitt Cancer Center
Robert Anders - Sidney Kimmel Comprehensive Cancer Center
Chandrakanth Are - Susan Thompson Buffett Foundation
Melinda Bachini - Cholangiocarcinoma Foundation
David Binder - University of Colorado Denver
Mitesh Borad
Christopher Bowlus - Sylvester Comprehensive Cancer Center
Daniel Brown - AbbVie
Adam Burgoyne - Fox Chase Cancer Center
Jason Castellanos - Apexigen
Prabhleen Chahal - Cleveland Clinic
Jordan Cloyd - The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Anne M. Covey - Memorial Sloan Kettering Cancer Center
Evan S. Glazer - University of Tennessee Health Science Center
William G. Hawkins - Jewish Hospital
Renuka Iyer - Apexigen
Rojymon Jacob - University of Colorado Denver
Lawrence Jennings - Janssen
R. Kate Kelley - UCSF Helen Diller Family Comprehensive Cancer Center
Robin Kim - Huntsman Cancer Institute
Matthew Levine - University of Pennsylvania
Manisha Palta - Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
James O. Park - Array BioPharma
Steven Raman - UCLA Jonsson Comprehensive Cancer Center
Sanjay Reddy - Janssen
Sean Ronnekleiv-Kelly - University of Wisconsin Carbone Cancer Center
Vaibhav Sahai - University of Michigan–Ann Arbor
Gagandeep Singh - City Of Hope National Medical Center
Stacey Stein - Smilow Cancer Hospital
Anita Turk - Indiana University
Jean-Nicolas Vauthey
Alan P. Venook - UCSF Helen Diller Family Comprehensive Cancer Center
Adam Yopp - The University of Texas Southwestern Medical Center
Nicole McMillian - National Comprehensive Cancer Network
Ryan Schonfeld - National Comprehensive Cancer Network
Cindy Hochstetler - National Comprehensive Cancer Network
Publication Details: JNCCN Journal of the National Comprehensive Cancer Network, Vol.21(7)
Publisher: Harborside Press
Identifiers: 991006165190402656
Language: English
Resource Type: Journal article